ArticleJournal of cancer research and clinical oncology2014
Retrospective study of neuroblastoma in Chinese neonates from 1994 to 2011: an evaluation of diagnosis, treatments, and prognosis : a 10-year restrospective study of neonatal neuroblastoma.
Article in Journal of cancer research and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of the study is to review the clinical features, treatments, and outcomes of neonatal neuroblastoma (NB).
methodsA retrospective analysis was performed on 42 patients with NB between January 1994 and December 2011.
resultsMYCN amplification was detected in nine tumor samples. The ratio of unfavorable histology to favorable histology was 1:2 in NB patients. The 5-year overall survival (OS) of NB patients was 85.7 %. The 5-year OS in patients in the operation group was 83.3 %, chemotherapy group was 83.3 %, and the "wait-and-see" group was 100 % (P = 0.04). Overall, the prognosis was favorable, except in patients with elevated MYCN amplification or vanillylmandelic acid.
conclusionsNB patients were more sensitive and vulnerable to chemotherapy and operation. The "wait-and-see" strategy should be highlighted in the treatment of NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.